CL2016003301A1 - Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma. - Google Patents
Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.Info
- Publication number
- CL2016003301A1 CL2016003301A1 CL2016003301A CL2016003301A CL2016003301A1 CL 2016003301 A1 CL2016003301 A1 CL 2016003301A1 CL 2016003301 A CL2016003301 A CL 2016003301A CL 2016003301 A CL2016003301 A CL 2016003301A CL 2016003301 A1 CL2016003301 A1 CL 2016003301A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- prostate
- bladder
- breast
- lung
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
La presente invención se refiere a un compuesto, o un estereoisómero o sal farmacéuticamente aceptable del mismo, que tiene la estructura de la fórmula (II): Además, la invención divulga el compuesto, o sal farmacéuticamente aceptable del mismo, de la reivindicación 1 de fórmula (IIa): Además, la presente invención divulga un método in vitro para inhibir una enzima JMJD3 de histona desmetilasa que comprende poner en contacto la enzima histona desmetilasa JMJD3 con un compuesto de fórmula (II), la presente invención divulga el uso del compuesto de fórmula (II).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017201P | 2014-06-25 | 2014-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016003301A1 true CL2016003301A1 (es) | 2021-03-05 |
Family
ID=54929774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016003301A CL2016003301A1 (es) | 2014-06-25 | 2016-12-22 | Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma. |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10385047B2 (es) |
| EP (3) | EP3160952B1 (es) |
| JP (1) | JP6521535B2 (es) |
| KR (1) | KR102591897B1 (es) |
| CN (2) | CN111909083B (es) |
| AR (1) | AR100997A1 (es) |
| AU (1) | AU2015279719B2 (es) |
| BR (1) | BR112016030367A2 (es) |
| CA (1) | CA2953437C (es) |
| CL (1) | CL2016003301A1 (es) |
| CO (1) | CO2017000359A2 (es) |
| CY (1) | CY1123906T1 (es) |
| DK (1) | DK3160952T3 (es) |
| EA (1) | EA031200B1 (es) |
| EC (1) | ECSP17004931A (es) |
| ES (1) | ES2862648T3 (es) |
| HR (1) | HRP20210299T1 (es) |
| HU (1) | HUE053876T2 (es) |
| IL (1) | IL249629A0 (es) |
| LT (1) | LT3160952T (es) |
| MX (1) | MX2016017407A (es) |
| NZ (1) | NZ728120A (es) |
| PL (1) | PL3160952T3 (es) |
| PT (1) | PT3160952T (es) |
| SA (1) | SA516380585B1 (es) |
| SG (1) | SG11201610813TA (es) |
| SI (1) | SI3160952T1 (es) |
| TW (2) | TWI715533B (es) |
| WO (1) | WO2015200709A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151417A1 (es) | 2012-12-21 | 2015-10-10 | Quanticel Pharmaceuticals Inc | Inhibidores de histona desmetilasa |
| AU2015279719B2 (en) | 2014-06-25 | 2019-03-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP6552608B2 (ja) | 2014-09-17 | 2019-07-31 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| CN108698997A (zh) * | 2015-12-28 | 2018-10-23 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| ES2921009T3 (es) * | 2016-03-15 | 2022-08-16 | Celgene Quanticel Res Inc | Inhibidores de desmetilasas de histonas |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US20180290977A1 (en) * | 2017-03-30 | 2018-10-11 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
| CN109825551B (zh) * | 2019-02-21 | 2022-08-02 | 深圳大学 | 一种评价组蛋白赖氨酸去甲基转移酶活性的方法 |
| CN111679072B (zh) * | 2020-06-15 | 2022-04-29 | 温州医科大学 | Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用 |
| WO2022217100A1 (en) * | 2021-04-09 | 2022-10-13 | Tachyon Therapeutics, Inc. | Treatment of cancer with kdm4 inhibitors |
| CA3227684A1 (en) * | 2021-08-18 | 2023-02-23 | Jr. Richard M. Heid | Process for preparing histone demethylase inhibitors |
| WO2023122221A1 (en) * | 2021-12-23 | 2023-06-29 | Tachyon Therapeutics, Inc. | Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid |
| TW202412816A (zh) | 2022-06-10 | 2024-04-01 | 美商弗沃德醫療公司 | ＴＮＦ—α活性調節劑 |
| WO2023250480A1 (en) * | 2022-06-23 | 2023-12-28 | The Cleveland Clinic Foundation | 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF |
| WO2024064734A1 (en) * | 2022-09-21 | 2024-03-28 | Celgene Corporation | Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2- yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4- yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor |
| CN115974647B (zh) * | 2022-12-05 | 2024-09-03 | 江苏宏邦化工科技有限公司 | 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| US8598168B2 (en) * | 2006-04-07 | 2013-12-03 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| EP2712655B1 (en) | 2011-04-28 | 2019-12-18 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) * | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| US20140162266A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc. | Methods for polymerase chain reaction copy number variation assays |
| US9604961B2 (en) * | 2012-12-06 | 2017-03-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| SI2934145T1 (en) * | 2012-12-19 | 2018-03-30 | Celgene Quanticel Research, Inc. | Histone demethyllase inhibitors |
| PE20151417A1 (es) | 2012-12-21 | 2015-10-10 | Quanticel Pharmaceuticals Inc | Inhibidores de histona desmetilasa |
| AU2015279719B2 (en) | 2014-06-25 | 2019-03-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US20180290977A1 (en) * | 2017-03-30 | 2018-10-11 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
-
2015
- 2015-06-25 AU AU2015279719A patent/AU2015279719B2/en active Active
- 2015-06-25 WO PCT/US2015/037812 patent/WO2015200709A1/en active Application Filing
- 2015-06-25 SI SI201531524T patent/SI3160952T1/sl unknown
- 2015-06-25 ES ES15811523T patent/ES2862648T3/es active Active
- 2015-06-25 EP EP15811523.8A patent/EP3160952B1/en active Active
- 2015-06-25 EA EA201692483A patent/EA031200B1/ru unknown
- 2015-06-25 JP JP2016574454A patent/JP6521535B2/ja active Active
- 2015-06-25 EP EP20184107.9A patent/EP3738960A1/en not_active Withdrawn
- 2015-06-25 MX MX2016017407A patent/MX2016017407A/es active IP Right Grant
- 2015-06-25 TW TW104120633A patent/TWI715533B/zh active
- 2015-06-25 EP EP20184106.1A patent/EP3741749A1/en active Pending
- 2015-06-25 CN CN202010813617.0A patent/CN111909083B/zh active Active
- 2015-06-25 HU HUE15811523A patent/HUE053876T2/hu unknown
- 2015-06-25 AR ARP150102042A patent/AR100997A1/es unknown
- 2015-06-25 TW TW109143458A patent/TWI758004B/zh active
- 2015-06-25 NZ NZ728120A patent/NZ728120A/en unknown
- 2015-06-25 KR KR1020177002223A patent/KR102591897B1/ko active IP Right Grant
- 2015-06-25 DK DK15811523.8T patent/DK3160952T3/da active
- 2015-06-25 CA CA2953437A patent/CA2953437C/en active Active
- 2015-06-25 PL PL15811523T patent/PL3160952T3/pl unknown
- 2015-06-25 LT LTEP15811523.8T patent/LT3160952T/lt unknown
- 2015-06-25 BR BR112016030367A patent/BR112016030367A2/pt not_active Application Discontinuation
- 2015-06-25 US US15/321,702 patent/US10385047B2/en active Active
- 2015-06-25 PT PT158115238T patent/PT3160952T/pt unknown
- 2015-06-25 US US14/751,007 patent/US9242968B2/en active Active
- 2015-06-25 SG SG11201610813TA patent/SG11201610813TA/en unknown
- 2015-06-25 CN CN201580045921.2A patent/CN106660982B/zh active Active
- 2015-12-09 US US14/963,754 patent/US9447046B2/en active Active
-
2016
- 2016-07-26 US US15/220,118 patent/US9586902B2/en active Active
- 2016-12-18 IL IL249629A patent/IL249629A0/en unknown
- 2016-12-22 CL CL2016003301A patent/CL2016003301A1/es unknown
- 2016-12-22 SA SA516380585A patent/SA516380585B1/ar unknown
-
2017
- 2017-01-09 US US15/402,100 patent/US9815828B2/en active Active
- 2017-01-16 CO CONC2017/0000359A patent/CO2017000359A2/es unknown
- 2017-01-24 EC ECIEPI20174931A patent/ECSP17004931A/es unknown
- 2017-10-24 US US15/792,570 patent/US9994561B2/en active Active
-
2018
- 2018-05-04 US US15/971,749 patent/US10106534B2/en active Active
-
2021
- 2021-02-23 HR HRP20210299TT patent/HRP20210299T1/hr unknown
- 2021-03-01 CY CY20211100169T patent/CY1123906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003301A1 (es) | Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma. | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| MX2015007205A (es) | Inhibidores de la desmetilasa de histona. | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
| ECSP15030527A (es) | Inhibidores de histona desmetilasa | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| EA201591296A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| BR112015030203A2 (pt) | moléculas pequenas inibidores da fibrose | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| ECSP17020172A (es) | Inhibidores de histona desmetilasa | |
| CL2017000659A1 (es) | Inhibidores de histona desmetilasa | |
| EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| MX2016001134A (es) | Derivados 1,3-disustituidos de ciclopentano. | |
| CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| NI201800043A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 | |
| CO2017003445A2 (es) | Inhibidores de la histona desmetilasa | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| ECSP19013196A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| AR081783A1 (es) | Esteres de metronidazol para tratar rosacea |